Samsung Biologics and TG Therapeutics expand collaboration on ublituximab

27 April 2021

South Korean contract development and manufacturing organization Samsung Biologics (KRX: 207940.KS) and US biotech TG Therapeutics (Nasdaq: TGTX) have announced an expansion of a large-scale contract manufacturing deal for the supply of TG Therapeutics’ ublituximab, an investigational anti-CD20 monoclonal antibody.

TG Therapeutics, whose shares closed up nearly 5% at $44.43 yesterday on the news, has completed a rolling submission of a Biologics License Application (BLA) to the US Food and Drug Administration requesting approval of ublituximab, in combination with Ukoniq (umbralisib), TG Therapeutics’ oral once-daily inhibitor of PI3K-delta and CK1-epsilon, as a treatment for patients with chronic lymphocytic leukemia (CLL), based primarily on the positive results from the UNITY-CLL Phase III trial. Ublituximab was also the subject of two successful Phase III trials in patients with relapsing forms of multiple sclerosis (RMS) and a BLA is currently being prepared for this indication.

Financial terms of the accord

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK